Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. How do we move towards a personalised approach in the treatment of Early Hodgkin lymphoma?

    Research output: Contribution to journalEditorialResearchpeer-review

  1. Classmates motivate childhood cancer patients to participate in physical activity during treatment: A qualitative study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Psychotropic Medication Use in Parents of Children Diagnosed With Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Sperm DNA Integrity is Unaffected by Thiopurine Treatment in Men With Inflammatory Bowel Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Insulin-dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m(2), ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m(2) per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m(2) per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.
Original languageEnglish
JournalBritish Journal of Haematology
Volume155
Issue number2
Pages (from-to)244-7
Number of pages4
ISSN0007-1048
DOIs
Publication statusPublished - 2011

    Research areas

  • 6-Mercaptopurine, Adolescent, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Dose-Response Relationship, Drug, Drug Administration Schedule, Feasibility Studies, Female, Fever, Humans, Individualized Medicine, Infant, Male, Methotrexate, Mucositis, Pancreatitis, Pilot Projects, Precursor Cell Lymphoblastic Leukemia-Lymphoma

ID: 33292073